Karam JA - Search Results

1

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Gomez DR, et al. Among authors: karam ja. Lancet Oncol. 2016 Dec;17(12):1672-1682. doi: 10.1016/S1470-2045(16)30532-0. Epub 2016 Oct 24. Lancet Oncol. 2016. PMID: 27789196 Free PMC article. Clinical Trial.

2

Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy.

Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Karam JA, et al. Lancet Oncol. 2007 Feb;8(2):128-36. doi: 10.1016/S1470-2045(07)70002-5. Lancet Oncol. 2007. PMID: 17267327

3

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.

Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Karam JA, et al. J Urol. 2011 Feb;185(2):439-44. doi: 10.1016/j.juro.2010.09.086. Epub 2010 Dec 17. J Urol. 2011. PMID: 21167518 Free PMC article.

4

The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.

Karam JA, Wood CG. Karam JA, et al. Hematol Oncol Clin North Am. 2011 Aug;25(4):753-64. doi: 10.1016/j.hoc.2011.05.002. Hematol Oncol Clin North Am. 2011. PMID: 21763966 Review.

5

Biomarkers of renal cell carcinoma.

Ngo TC, Wood CG, Karam JA. Ngo TC, et al. Among authors: karam ja. Urol Oncol. 2014 Apr;32(3):243-51. doi: 10.1016/j.urolonc.2013.07.011. Epub 2013 Nov 13. Urol Oncol. 2014. PMID: 24239464 Review.

6

Partial nephrectomy in the setting of metastatic renal cell carcinoma.

Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Babaian KN, et al. Among authors: karam ja. J Urol. 2014 Jul;192(1):36-42. doi: 10.1016/j.juro.2014.01.086. Epub 2014 Feb 8. J Urol. 2014. PMID: 24518767 Free PMC article.

7

Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.

Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Karam JA, et al. Eur Urol. 2014 Nov;66(5):874-80. doi: 10.1016/j.eururo.2014.01.035. Epub 2014 Feb 7. Eur Urol. 2014. PMID: 24560330 Free PMC article. Clinical Trial.

8

Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.

Culp SH, Karam JA, Wood CG. Culp SH, et al. Among authors: karam ja. Urol Oncol. 2014 Jul;32(5):561-8. doi: 10.1016/j.urolonc.2013.12.003. Epub 2014 Apr 4. Urol Oncol. 2014. PMID: 24709415

9

Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.

Kim DY, Karam JA, Wood CG. Kim DY, et al. Among authors: karam ja. World J Urol. 2014 Jun;32(3):631-42. doi: 10.1007/s00345-014-1293-6. Epub 2014 Apr 18. World J Urol. 2014. PMID: 24744223 Review.

10

Role of partial nephrectomy as cytoreduction in the management of metastatic renal cell carcinoma.

Karam JA, Babaian KN, Tannir NM, Matin SF, Wood CG. Karam JA, et al. Minerva Urol Nefrol. 2015 Jun;67(2):149-56. Epub 2015 Feb 3. Minerva Urol Nefrol. 2015. PMID: 25645343 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

288 results

Search Page